Michelle I. Lin

Michelle I. Lin

Family Medicine
2100 Erwin Rd
Durham, NC 27705

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Uncovering molecular and functional dynamics of human hematopoietic stem cells during in vitro culture for cell therapy manufacturing.

Uncovering molecular and functional dynamics of human hematopoietic stem cells during in vitro culture for cell therapy manufacturing.

Journal: Cytotherapy
Published: November 18, 2025

Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).

Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).

Journal: JCO precision oncology
Published: October 23, 2025

Clonal Dynamics, Tolerance, and Adverse Events After CD45-ADC-Conditioned Autologous HSPC Transplantation in Macaques.

Clonal Dynamics, Tolerance, and Adverse Events After CD45-ADC-Conditioned Autologous HSPC Transplantation in Macaques.

Journal: Blood advances
Published: August 26, 2025

Clonal dynamics, tolerance, and adverse events after CD45-ADC-conditioned autologous HSPC transplantation in macaques.

Clonal dynamics, tolerance, and adverse events after CD45-ADC-conditioned autologous HSPC transplantation in macaques.

Journal: Blood advances
Published: August 26, 2025

CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.

CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.

Journal: Nature medicine
Published: August 01, 2025

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

Journal: Blood
Published: July 31, 2025

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

Journal: Blood
Published: July 31, 2025

Erratum: Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity.

Erratum: Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity.

Journal: Molecular therapy. Methods & clinical development
Published: December 14, 2023

Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity.

Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity.

Journal: Molecular therapy. Methods & clinical development
Published: June 23, 2023
Showing 1-9 of 9

Last Updated: 09/26/2026